医学
药物治疗
类阿片
回顾性队列研究
儿科
怀孕
急诊医学
麻醉
内科学
遗传学
受体
生物
作者
Lisa Chyi,Sherian Li,Catherine Lee,Eileen M. Walsh,Michael W. Kuzniewicz
标识
DOI:10.1177/00099228231204448
摘要
Compared with the Finnegan Neonatal Abstinence Scoring System (FNASS), the Eat, Sleep, Console (ESC) approach reduces pharmacotherapy and length of stay (LOS) for neonatal opioid withdrawal syndrome (NOWS) infants. The independent outcome contribution of ESC is unknown as the approach combines ESC assessment with additional management changes. Our objective was to evaluate ESC assessment’s independent impact on outcomes compared with FNASS. We conducted a retrospective cohort study of in utero opioid-exposed infants ≥35 weeks gestation managed with FNASS versus ESC. Outcomes included pharmacotherapy initiation, LOS, length of pharmacotherapy, and emergency department visit/readmissions. Among 151 FNASS and 100 ESC managed infants, pharmacotherapy initiation ( P = .47), LOS for all infants ( P = .49), and LOS for pharmacologically treated infants ( P = .68) were similar. Length of pharmacotherapy did not differ ( P = .84). Emergency department evaluation/NOWS readmission was equally rare ( P = .65). Using equivalent models of care, comparison of ESC and FNASS assessment tools showed no difference in NOWS outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI